Antisense oligonucleotides (ASOs) represent a promising therapeutic modality, but their efficacy and safety are intrinsically linked to their absorption, distribution, metabolism, and excretion (ADME) characteristics. Understanding these pharmacokinetic (PK) properties is crucial for optimizing ASO drug development. The absorption of ASOs is influenced by their specific physicochemical properties, such as ionization state, acid dissociation constant (pKa), and hydrophobicity, as well as the chosen route of administration. Subsequent drug distribution is then governed by factors including the administration route, concentration of free drug, tissue blood perfusion, extent of tissue binding, local pH environment, and cell membrane permeability.
Impact of ASO Chemistry on Plasma Protein Binding and Distribution
First and second-generation phosphorothioate (PS)-modified ASOs, due to their negatively charged backbone, exhibit high binding affinity to plasma proteins, particularly albumin (often >85%). For instance, Mipomersen shows plasma protein binding of 95% in humans and 85% in mice. In contrast, ASOs with phosphorodiamidate morpholino oligomer (PMO) modifications are uncharged and demonstrate significantly lower plasma protein binding in humans (e.g., 6-17% for Eteplirsen, specifically 6.1%-16.5%).
This difference in plasma protein binding has profound implications. Since protein binding influences cellular uptake and glomerular filtration, PS-ASOs generally exhibit more sustained tissue distribution and slower urinary excretion compared to PMOs.
Systemic Administration Routes: Challenges and Strategies
- Oral Administration: Both PS-ASOs and PMOs generally have poor oral absorption. Their large molecular weight and hydrophilic nature result in low membrane permeability.
- Intravenous (IV) and Subcutaneous (SC) Injection: While oral delivery is challenging, systemic exposure can be reliably achieved via IV or SC injection following appropriate chemical modifications. Currently, most ASOs are administered intravenously to maximize bioavailability. This route facilitates rapid distribution to highly vascularized organs such as the liver, kidneys, and spleen. However, distribution to tissues like the heart, muscle, and lungs is slower, potentially necessitating more frequent dosing. For example, weekly IV administration of Eteplirsen (30 mg/kg) in clinical trials showed an average apparent volume of distribution (Vd) of 601 ml/kg, indicating substantial tissue distribution. Following single or multiple IV doses, Cmax typically occurs at the end of the infusion, and PK often demonstrates dose proportionality with repeat dosing.
- Subcutaneous Administration: SC administration often results in a longer distribution half-life compared to IV, likely due to gradual absorption from the injection site. A study in non-human primates (NHPs) with Eteplirsen (320 mg/kg) showed 100% bioavailability following SC administration, with Cmax occurring approximately 7 hours post-dose. Mipomersen also demonstrated complete absorption from the SC site in monkeys, with 100% bioavailability and Cmax at 3-4 hours. The team at Prisys Biotech has extensive experience in designing and conducting such NHP studies for ASO characterization.
Cellular Uptake and Intracellular Trafficking Mechanisms
Due to their limited membrane permeability, ASOs enter cells primarily via phagocytosis or receptor-mediated endocytosis, rather than passive diffusion. This cellular uptake is a multi-step process:
- Adsorption: ASOs initially adsorb to cell surface proteins.
- Internalization: Various cell surface receptors, including epidermal growth factor receptors (EGFRs), G protein-coupled receptors (GPCRs), and scavenger receptors, mediate ASO endocytosis. Scavenger receptors, in particular, have been well-studied; stabilin-1 and stabilin-2 mediate hepatic uptake of PS-ASOs, while scavenger receptor A1 mediates muscle uptake of PMOs.
Once internalized, ASOs must escape from endosomes to interact with their target RNA in the cytoplasm or nucleus. This intracellular trafficking is regulated by interactions with numerous cytoplasmic and nuclear proteins. For PS-ASOs, studies by Liang et al. identified a suite of interacting intracellular proteins. More recently, Rab5C and early endosome antigen 1 (EEA1) have been implicated in the early endosomal trafficking of PS-ASOs, promoting their endosomal escape after stabilin-mediated internalization. In the late endosomal pathway, Rab7A and lysosomal bis(monoacylglycero)phosphate are involved. The molecular basis of intracellular transport for PMOs is less well understood compared to PS-ASOs.
Strategies to Optimize ASO Tissue Distribution
To enhance tissue-specific delivery and overall distribution profiles, several strategies are being explored:
- Conjugation: Conjugating ASOs to targeting moieties like fatty acids or peptides is a key approach. For instance, (GalNAc3)-ASO conjugates, which are actively taken up by hepatocytes via the asialoglycoprotein receptor, have entered clinical development, demonstrating significantly improved liver-targeted delivery and enhanced pharmacodynamics.
- Cell-Penetrating Peptides (CPPs): Coupling ASOs with CPPs is another successful method to improve cellular penetration. The positive charge of CPPs facilitates binding to uncharged PMO ASOs. CPPs promote PMO entry into cells via endocytic mechanisms involving interactions between the cationic CPP and anionic cell surface proteoglycans. This strategy has been effectively used to enhance PMO uptake in muscle tissue.
Local Administration for Targeted Delivery
For target sites inaccessible or poorly reached by systemic administration, direct local ASO delivery is a viable option.
- Ocular Delivery: Intravitreal injection, as used for Fomivirsen, delivers the drug directly to the eye, requiring only small doses for direct retinal distribution.
- Central Nervous System (CNS) Delivery: Intrathecal (IT) administration bypasses the blood-brain barrier, enabling ASO delivery to the CNS. Although invasive, IT injection has proven effective in increasing ASO bioavailability in the brain and spinal cord while minimizing systemic exposure compared to IV or SC routes. The success of Nusinersen via IT administration highlights the potential of ASOs for CNS disorders and opens avenues for targeting conditions like Huntington's disease and amyotrophic lateral sclerosis. Single IT injections in adult cynomolgus monkeys have shown widespread distribution in the spinal cord at pharmacologically active levels. Seven days post-dose, total nusinersen levels in CNS tissues were dose-dependent, with higher distribution in the spinal cord and cortex. Even at the lowest dose (1 mg/kg), drug levels in target tissues were 3-8 times higher than the EC50 (~1 µg/g). Developing and validating such specialized CNS delivery protocols is a core competency at Prisys Biotech.
- Intranasal Delivery: Intranasal administration is being explored as a non-invasive route for CNS delivery of ASOs. Following intranasal application, ASO molecules can be transported via pathways like the olfactory and trigeminal nerves. The use of CPPs may further enhance CNS delivery, a strategy that has shown promise with siRNAs.
Oral Bioavailability: An Ongoing Challenge
Oral administration remains a significant hurdle for ASOs due to limited gastrointestinal absorption. The PS-ASO ISIS 14725 showed an oral bioavailability of approximately 5.5% after duodenal administration in rats, while the PMO AVI-4472 demonstrated oral bioavailability of 41%-79% in rats. However, reports of successful oral PMO administration in humans are currently lacking.
Conclusion: The Importance of Pharmacokinetic Understanding in ASO Development
The absorption and distribution of ASO drugs are complex processes dictated by their chemical nature and the chosen delivery strategy. A thorough understanding of these pharmacokinetic principles, from plasma protein binding and cellular uptake mechanisms to the impact of different administration routes, is paramount for designing and developing safe and effective ASO therapies. Continued research into novel delivery technologies and chemical modifications aims to further optimize ASO biodistribution and therapeutic efficacy. Partnering with experienced preclinical contract research organizations (CROs) like Prisys Biotech, which possess deep expertise in ASO characterization and specialized delivery techniques, can significantly contribute to the successful advancement of these innovative medicines.
